Cancer Research receives increased backing from AstraZeneca
This article was originally published in Scrip
Executive Summary
AstraZeneca is to double its investment in Cancer Research UK's biomarker research programme, enabling the charity to process up to 30,000 biomarker assays a year for the next three years.